All In Biotech

Drug Trial Radar · NCT00460317

MONET1-MOtesanib NSCLC Efficacy and Tolerability Study

A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial of AMG 706 in Combination With Paclitaxel and Carboplatin for Advanced Non-small Cell Lung Cancer.

Last checked: Nov 19, 2026Latest source record: Sep 7, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. Randomized with 1,450 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

1,450

Actual

Start

Jul 2007

Primary completion

Mar 2011

Study completion Aug 2013

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
Collaborators
Takeda
First posted
Apr 13, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To determine if treatment with AMG 706 (motesanib diphosphate) in combination with paclitaxel and carboplatin improves overall survival compared to treatment with placebo in combination with paclitaxel and carboplatin in subjects with advanced non-squamous NSCLC and in subjects with adenocarcinoma histology (adenocarcinoma subpopulation).

Conditions

  • Non-Small Cell Lung Cancer

Interventions

  • AMG 706Drug

    125 mg QD orally every day

  • placeboDrug

    125 mg QD orally every day

  • paclitaxelDrug

    200mg/m2 on day 1 of each 3 week cycle +/- 3 days for a max of 6 cycles

  • carboplatinDrug

    AUC of 600mg/mL x min by Calvert formula on day 1 of each 3 week cycle +/- 3 days for a max of 6 cycles

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survival time. Time from randomization to death. Subjects who have not died while on study or are lost to follow up will be censored at their last contact date.Time frame: Not able to be measured

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.